Extended Data Table 4 Geometric mean (mean, % CV) budigalimab pharmacokinetic parameters following Q2W administration in stage II

From: Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study